Mary Caffrey
Advertisement
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles by Mary Caffrey
New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.
We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.
Matthew Zachary, the keynote speaker for Patient-Centered Oncology Care 2024, recalls what the treatment experience was like when he was diagnosed with a rare pediatric brain cancer in 1996. Zachary is now a patient advocate.
A long-awaited report from the Federal Trade Commission (FTC) finds that vertical integration and consolidation have worked against consumers and independent pharmacies.
Researchers from the University of Manchester sought to understand whether the season of administration of immunotherapy affected outcomes.
A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
Interview on Ontada research presented at ISPOR 2024.
At a symposium on the impact of the Inflation Reduction Act (IRA) on pharmaceutical innovation and access, speakers urged the audience to join in advocating for changes to the law.
Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.
Coverage of a session on antibody drug conjugates from the 2024 American Society of Clinical Oncology Annual Meeting.
The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.
An in-depth analysis of minimal residual disease (MRD) negativity results from the PERSEUS trial shows patients whose treatment regimen included subcutaneous daratumumab had responses that deepened over time.
Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.
Results for the first 10 patients offer promising signs for giving patients with multiple myeloma a prophylactic dose of tocilizumab before they are treated with the bispecifc antibody teclistamab.
The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.
Within the GAIN-S model, geriatric care assessments among older patients with cancer are combined with care interventions, and it is delivered soon before patients have an intervention on their cancer therapy, says William Dale, MD, PhD, FASCO, City of Hope.
A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer.
The BE-a-PAL study investigated potential of an algorithm-based default palliative care referral among patients who have stage III or IV lung or noncolorectal gastrointestinal cancer.
Attendees packed a session on multicancer early detection (MCED) on the first day of the 2024 American Society of Clinical Oncology annual meeting.
The annual session on newly approved drugs reviewed adverse effects, mechanisms of action, and real-world experiences.
Glofitamab is currently being investigated in a phase 1/2, multicenter, open-label, dose-escalation study as monotherapy and in combination with obinutuzumab, following 1-time fixed-dose pretreatment with obinutuzumab for B-cell non-Hodgkin lymphoma, of which mantle cell lymphoma (MCL) is a rare type.
The Enhancing Oncology Model (EOM) attracted fewer participants than its predecessor, with lower payment rates cited as a chief factor.
Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy.
Topics at the upcoming meeting of the American Society of Clinical Oncology include the impact of artificial intelligence and the best way to deliver palliative care.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
2
Value-Based Care Interventions and Management of CKD Progression
3
Better Food, Better Health: Redefining Chronic Disease Care Through Nutrition
4
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
5
